A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in High Volume Metastatic Castration Sensitive Prostate Cancer

Masonic Cancer Center, University of Minnesota8 sites in 1 country22 target enrollmentOctober 10, 2019

ConditionsProstate Cancer

InterventionsCabazitaxel Carboplatin Abiraterone Prednisone

DrugsCabazitaxel Carboplatin Abiraterone Prednisone

Overview

Phase: Phase 2
Intervention: Cabazitaxel
Conditions: Prostate Cancer
Sponsor: Masonic Cancer Center, University of Minnesota
Enrollment: 22
Locations: 8
Primary Endpoint: Prostate-Specific Antigen (PSA) or Radiographic Progression
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin and cabazitaxel for 6 cycles. After 6 cycles of chemotherapy, they will start abiraterone with ADT. The primary objective is to determine the percent of subjects that have no PSA or radiographic progression at 1 year. Secondary objectives will include determining the progression-free survival, time to PSA nadir and time to PSA progression of carboplatin and cabazitaxel in combination with ADT.

Registry

clinicaltrials.gov

Start Date

October 10, 2019

End Date

May 2025

Last Updated

2 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Male

Investigators

Sponsor

Masonic Cancer Center, University of Minnesota

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Willing and able to provide, or have a legally authorized representative provide, written informed consent and HIPAA authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.
•Histologically confirmed prostate cancer.
•High volume metastatic disease (defined as the presence of visceral metastases or ≥3 bone lesions).
•ADT for ≤3 months by day 1 of study chemotherapy; Prior episodes of ADT are allowed (i.e. ADT used previously in courses of radiation).
•Testosterone \<50 ng/dL. Patients must continue primary ADT with an LHRH analogue if they have not undergone orchiectomy.
•ECOG Performance Status 0 or 1 (see Appendix A)
•Patient has adequate bone marrow and organ function as defined by the following laboratory values:
•Absolute neutrophil count ≥ 1.5 × 10\^9/L
•Platelets ≥ 100 × 10\^9/L
•Hemoglobin ≥ 9 g/dl

Exclusion Criteria

•Prior exposure to any chemotherapy, PARPi, or immunotherapy for prostate cancer.
•Prior abiraterone or enzalutamide, unless therapy was for \< 2 weeks
•Radiation therapy (including palliative radiotherapy to a metastatic lesion) within 14 days or major surgery (e.g., open abdominal, pelvic, thoracic, orthopedic or neurosurgery) within 28 days of the date of the first dose.
•Other systemic therapies for prostate cancer within 28 days or 5 half-lives, whichever is shorter, prior to day 1 of chemotherapy (with the exception of anti-androgens like bicalutamide).
•PSA \<2.0 ng/mL at diagnosis.
•If present, peripheral neuropathy must be ≤ Grade 1
•Patients with an active second malignancy that could, in the investigator's opinion, potentially interfere with the patient's ability to participate and/or complete this trial.
•Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:
•At least 4 weeks from prior therapy completion (including radiation and/or surgery) prior to starting the study treatment
•Clinically stable CNS tumor at the time of screening.